|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400086857 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-12 14:59:20 |
|
注册时间: Date of Registration: |
2024-07-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
糖尿病孕妇胎儿胸腺发育的超声评估 |
|
Public title: |
Ultrasonic evaluation of fetal thymus development in diabetes pregnant women |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
糖尿病孕妇胎儿胸腺发育的超声评估 |
|
Scientific title: |
Ultrasonic evaluation of fetal thymus development in diabetes pregnant women |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
温慧芳 |
研究负责人: |
温慧芳 |
|
Applicant: |
Wen Huifang |
Study leader: |
Wen Huifang |
|
申请注册联系人电话: Applicant telephone: |
+86 13413515057 |
研究负责人电话: Study leader's telephone: |
+86 13413515057 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
173045083@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
173045083@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省清远市银泉北路清远市人民医院妇产科b超声 |
研究负责人通讯地址: |
银泉北路35号 |
|
Applicant address: |
Ultrasound of Obstetrics and Gynecology at Qingyuan People's Hospital, Yinquan North Road, Qingyuan |
Study leader's address: |
No.35,Yinquan North Road,Qingcheng District,Qingyuan Guangdong,China, |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广州医科大学附属清远医院(清远市人民医院) |
||
|
Applicant's institution: |
Qingyuan Hospital Affiliated to Guangzhou Medical University (Qingyuan People's Hospital) |
||
|
研究负责人所在单位: |
广州医科大学附属清远医院(清远市人民医院) |
||
|
Affiliation of the Leader: |
Affiliated Qingyuan Hospital, Guangzhou Medical University,Qingyuan People's Hospital; |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
IRB-2024-080 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州医科大学附属清远医院(清远市人民医院)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Qingyuan Peoples Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-05-24 00:00:00 |
||
|
伦理委员会联系人: |
邓源武 |
||
|
Contact Name of the ethic committee: |
Deng Yuanwu |
||
|
伦理委员会联系地址: |
银泉北路35号 |
||
|
Contact Address of the ethic committee: |
No.35,Yinquan North Road,Qingcheng District,Qingyuan Guangdong,China, |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 763 3113629 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
545898604@qq.com |
|
研究实施负责(组长)单位: |
广州医科大学附属清远医院(清远市人民医院) |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Qingyuan Hospital, Guangzhou Medical University,Qingyuan People's Hospital; |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
银泉北路35号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.35,Yinquan North Road,Qingcheng District,Qingyuan Guangdong,China, |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
糖尿病孕妇胎儿胸腺发育的超声评估 |
||||||||||||||||||||||
|
Source(s) of funding: |
Ultrasonic evaluation of fetal thymus development in diabetes pregnant women |
||||||||||||||||||||||
|
Target disease: |
Healthy pregnancy and pregnant women with diabetes |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
析因分组(即根据危险因素或暴露因素分组) |
||||||||||||||||||||||
|
Study design: |
Factorial |
||||||||||||||||||||||
|
研究目的: |
通过超声检查测量糖尿病孕妇与健康孕妇的胎儿胸腺大小,评估孕妇糖尿病与胎儿胸腺发育之间的相关性,以及不同类型糖尿病的胎儿胸腺大小是否存在差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
The size of fetal thymus of pregnant women with diabetes and healthy pregnant women was measured by ultrasound to evaluate the correlation between pregnant women with diabetes and fetal thymus development, and whether there was difference in the size of fetal thymus of different types of diabetes. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
组1: (1)孕妇妊娠前根据《中国2型糖尿病防治指南(2020年版)》、《中国1型糖尿病防治指南(2021版)》确诊为糖尿病,或妊娠前正常但妊娠期确诊为妊娠糖; (2)孕妇年龄20-45岁,BMI范围18~35; (3)孕龄18周-40周,胎儿大小与孕周相符,单胎妊娠; (4)自愿签署知情同意书; 组2: (1)妊娠前符合健康人群特征,无基础疾病,且妊娠期无相关妊娠并发症,属于健康孕妇。 (2)孕妇年龄20-45岁,BMI范围18~35; (3)孕龄18周-40周,胎儿大小与孕周相符,单胎妊娠; (4)自愿签署知情同意书; |
||||||||||||||||||||||
|
Inclusion criteria |
Group 1: (1) Pregnant women were diagnosed with diabetes before pregnancy according to the Guidelines for the Prevention and Treatment of Type 2 diabetes in China (2020 Edition) and the Guidelines for the Prevention and Treatment of Type 1 diabetes in China (2021 Edition), or they were normal before pregnancy but were diagnosed with gestational diabetes during pregnancy; (2) Pregnant women aged 20-45, BMI range 18-35; (3) Pregnancy age of 18-40 weeks, fetal size matching gestational age, single pregnancy; (4) Voluntary signing of informed consent form; Group 2: (1) Pregnant women who meet the characteristics of a healthy population before pregnancy, have no underlying diseases, and have no related pregnancy complications during pregnancy are considered healthy pregnant women. (2) Pregnant women aged 20-45, BMI range 18-35; (3) Pregnancy age of 18-40 weeks, fetal size matching gestational age, single pregnancy; (4) Voluntary signing of informed consent form; |
||||||||||||||||||||||
|
排除标准: |
1.涉及本研究收集指标的临床病历资料不完整; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.The clinical medical record data related to the collected indicators in this study is incomplete; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-15 00:00:00至 To 2025-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-07-15 00:00:00 至 To 2025-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
nothing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
所有收集的原始数据文件专人保存,并整理成用于统计分析的电子文档数据,进行数据统计分析。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
All collected raw data files shall be kept by a dedicated person and organized into electronic documents for statistical analysis. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |